Immunosuppression and growth factors for severe aplastic anemia: new data for old questions
Open Access
- 1 May 2020
- journal article
- editorial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 105 (5), 1170-1171
- https://doi.org/10.3324/haematol.2020.246512
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Eltrombopag Added to Standard Immunosuppression for Aplastic AnemiaThe New England Journal of Medicine, 2017
- How I treat acquired aplastic anemiaBlood, 2017
- How I treat acquired aplastic anemiaBlood, 2012
- Eltrombopag and Improved Hematopoiesis in Refractory Aplastic AnemiaThe New England Journal of Medicine, 2012
- A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow TransplantationBlood, 2011
- Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysisHaematologica, 2009
- Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in JapanBlood, 2007
- Immunosuppressive therapy for acquired severe aplastic anemia (SAA): A prospective comparison of four different regimensExperimental Hematology, 2006
- Results and follow‐up of a phase III randomized study of recombinant human‐granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemiaBritish Journal of Haematology, 2002
- Late clonal diseases of treated aplastic anemiaSeminars in Hematology, 2000